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ABSTRACT The glucose transporters (GLUT/SLC2A) are members of the major facilitator superfamily. Here, we generated
a three-dimensional model for Glut1 using a two-step strategy: 1), GlpT structure as an initial homology template and 2),
evolutionary homology using glucose-6-phosphate translocase as a template. The resulting structure (PDB No. 1SUK) exhibits
a water-ﬁlled passageway communicating the extracellular and intracellular domains, with a funnel-like exofacial vestibule
(infundibulum), followed by a 15 A˚-long 3 8 A˚-wide channel, and a horn-shaped endofacial vestibule. Most residues which, by
mutagenesis, are crucial for transport delimit the channel, and putative sugar recognition motifs (QLS, QLG) border both ends of
the channel. On the outside of the structure there are two positively charged cavities (one exofacial, one endofacial) delimited
by ATP-binding Walker motifs, and an exofacial large side cavity of yet unknown function. Docking sites were found for the
glucose substrate and its inhibitors: glucose, forskolin, and phloretin at the exofacial infundibulum; forskolin, and phloretin at an
endofacial site next to the channel opening; and cytochalasin B at a positively charged endofacial pocket 3 A˚ away from the
channel. Thus, 1SUK accounts for practically all biochemical and mutagenesis evidence, and provides clues for the transport
process.
INTRODUCTION
The major facilitator superfamily (MFS, TC No. 2.A.1) is
a grouping of TM proteins that transport a wide range of
solutes such as amino acids, sugars, nucleotides, organic and
inorganic anions, metabolites, neurotransmitters, polyols,
etc. (Marger and Saier, 1993). This superfamily, which has
over a thousand sequenced members, is present from bacteria
to eukaryotes, and includes the glucose transporter facilitator
family (GLUT/SLC2A, TC No. 2.A.1.1.28; see Pao et al.,
1998). GLUT1 was initially cloned and sequenced from
HepG2 cells in 1985 (Mueckler et al., 1985). The cDNA
encodes a TM protein of 492 residues (calculated molecular
weight 54.2 kDa). There is extensive functional and
structural and information on Glut1, obtained bymutagenesis
studies on accessibility for cysteins, labeling with mercurial
reagents, use of inhibitors for substrate inﬂux and efﬂux, use
of labeled metabolites, antibodies, and digestion by proteases
(Hruz and Mueckler, 2001). On the basis of this information
plus the prediction of TM helical segments, it is theorized that
this protein is constituted by 12 TM helices in two 6-helical
domain halves separated by the large intercellular loop
between H6 and H7. Consistent with this, putative helical
regions contain residues that have been identiﬁed as crucial
for transport function: G75, G76, G79, N288, and A289
(Olsowski et al., 2000); Q161 (Seatter et al., 1998; Mueckler
et al., 1994); V165 (Mueckler and Makepeace, 1997); N317,
T321, and P387 (Mueckler and Makepeace, 2002); Q282
(Hruz and Mueckler, 1999; Olsowski et al., 2000); I287
(Hruz and Mueckler, 1999); W388 (Kasahara and Kasahara,
1998; Garcia et al., 1992); and W412 (Garcia et al., 1992).
Exploration of the topology is also consistent with the
12-helix scheme. As illustrations, a conserved motif RXGRR
is found in both loops 2–3 and 8–9 (residues R89–R93 and
R330–R334, respectively; Sato and Mueckler, 1999). The
glycosylation site is at N45, as determined by SDS-PAGE
and conﬁrmed by mutagenesis (Asano et al., 1991), and
labeling with biotin revealed the extracellular location of
residue K300 in the putative loop 7–8 (Preston and Baldwin,
1993).
Studies in patients with the glucose transporter-1 de-
ﬁciency syndrome (see De Vivo et al., 1991) have located
eight more residues crucial for transport in both helical and
loop regions: S66 and T310 (Klepper et al., 1999); G91
(Klepper et al., 2001); R126 (Pascual et al., 2002;
Brockmann et al., 2001; Wang et al., 2000); E247 and
K256 (Pascual et al., 2002); and E146 and R333 (Wang et al.,
2000). Recently, studies have appeared in which the
previously unknown structure ofMFS 12 TM helical proteins
has been solved by crystallography. An electronic density
map for the oxalate transporter OxlT (TC No. 2.A.1.11.1)
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from Oxalobacter formigens was solved to 6.5 A˚ resolution
(Hirai et al., 2002), and subsequently the structures of the
glycerol 3-phosphate antiporter GlpT from Escherichia coli
(TC No. 2.A.1.4.3; see Huang et al., 2003) and the lactose
permease proton symporter LacY from E. coli (TC No.
2.A.1.5.1, see Abramson et al., 2003) were solved at 3.3 A˚
and 3.5 A˚ resolution, respectively.
In lieu of missing crystallographic studies, a few models
for Glut1 have been previously advanced. Gould and Holman
(1993) based theirs on a hypothetic arrangement of two
6-helical TM domains. Subsequently, Zeng et al. (1996)
proposed two possible schemes for helical packing using
clusters of four transmembrane segments surrounding a
central water-accessible channel for the substrate. A model
of Glut3 was built on the basis of the crystallographic
structure of a mechanosensitive channel of large conduc-
tance, plus general insights from aquaporin 1 (Dwyer, 2001),
and a model for Glut1 was developed by us based on a prior
scheme for LacY helical packing (Zuniga et al., 2001).
In an alignment of the sequences of the three MFS proteins
recently crystallized (OxlT, GlpT, and LacY), the homology
difference is 77.5%. However, the secondary structures and
helical packing are markedly homologous, which indicates
that there may be a universal fold for this family. Therefore it
seems feasible to model MFS proteins by homology with
those already crystallized, and to compare the resulting
structure with experimental results such as those on acces-
sibilities, solvent-exposed surface, densities, helicity, ener-
gies, and docking with substrates and inhibitors. We have
presently done this for GLUT1; the structure obtained ac-
counts for the biochemical and mutagenic evidence, and
gives insight on the molecular mechanism of substrate
migration, protein ﬂexibility, and binding sites for glucose
and the best-known inhibitors, forskolin, phloretin, and cy-
tochalasin B (CytB). Importantly, the eight residues whose
mutation leads to pathogenesis are seen to be located in the
immediate vicinity of the transport channel, and are in
a region of high relative mobility.
MATERIALS AND METHODS
Homology building
We developed two models, Glut1A and Glut1B. Glut1A was done by
homology with the crystal structure of GlpT from E. coli (PDB No. 1PW4,
see Huang et al., 2003); similarly, GLUT1B corresponded to the structure of
LacY from E. coli (PDB No. 1PV6, see Abramson et al., 2003). The
alignments were done with ClustalW (Thompson et al., 1994) and
BLOSUM62 (Henikoff and Henikoff, 1992), with gap penalties of 10 for
insertion and 0.1 for extension. As constraints, we used residues
experimentally determined to be in loops, namely the glycosylation site
N45, the conserved motifs of loops 2–3 and loop 8–9 (89/330RXGRR93/
334; see Sato and Mueckler, 1999), loop 6–7 residues 213–269, loop 7–8
K300 (Preston and Baldwin, 1993), and loop 11–12 C429. The homology
modeling was done with Nest, a program inside the JACKAL suite (Xiang
and Honig, 2001) and reﬁnement with MODELLER (Sali and Blundell,
1993). For validation we used PROCHECK (Laskowki et al., 1993),
WHATCHECK (van Aalten et al., 1996), and molecular docking experi-
ments. For the correct assignments of residues to transmembrane helices 1
and 2 we used evolutionary modeling; we aligned the templates (Swiss-Prot
No. P08194) with a homologous human protein obtained searching with
PSIBLAST (Altschul et al., 1997), glucose 6-phosphate translocase from
Homo sapiens (Swiss-Prot No. O43826), with a homology difference of
40.2%.
Molecular dynamics simulations (MDS)
We used the force-ﬁeld GROMOS43a (van Gunsteren et al., 1996). The
protein was placed in a water box (solvation layer of ;7 A˚ thickness). All
runs were at 300 K with a time step of 2 fs. All bonds were constrained using
the LINCS (Hess et al., 1997) algorithm for the protein and SETTLE
(Miyamoto and Kollman, 1992) for water. We performed runs for 400 ps
and for 2 ns. We used Berendsen’s scheme for temperature and pressure
coupling for both protein and solvent (water). Electrostatic forces were
calculated with the particle-mesh Ewald algorithm. Initial energy minimi-
zation was done with the steep descent algorithm (1000 steps) followed by
conjugate gradient to a maximum force of 0.1 KJ mol1 nm1. All
simulations were performed with the MDS package GROMACS v3.14
(Lindahl et al., 2001; Berendsen et al., 1995). For trajectory analysis we used
the tools included in GROMACS and VMD v1.82 (Humphrey et al., 1996);
the ﬁrst 100 ps (equilibration) were neglected.
Transport channel prediction
To determine the passageway and cavities graphically we used VOIDOO
(Kleywegt and Jones, 1994) to generate the protein surface with a probe
radius of 1.2 A˚ and grid spacing of 0.5 A˚. Subsequently we used MAPMAN
(Kleywegt and Jones, 1996) to convert between the .ezd and .mask formats,
and the passageway surface was calculated using the script cavities.mamac
in the program MAMA (Kleywegt and Jones, 1999). We used VMD
(Humphrey et al., 1996) to display graphical images.
Docking
The ligand coordinates for b-D-glucose and forskolin were obtained from
the PDBsum database (Laskowski et al., 1997; http://www.biochem.ucl.
ac.uk/bsm/pdbsum); phloretin and CytB were built manually and optimized
with the MM1 force ﬁeld in HYPERCHEM. A GROMACS-compatible ﬁle
for dihedrals and topology was generated for each with the server PRODGR
(van Aalten et al., 1996) using the total-charge option, and not minimized.
We prepared the initial Glut1A model for docking by running the 400-ps
MDS in water referred to above. Docking for each ligand was explored
separately using ZDOCK 2.3 (Chen and Weng, 2002) in its default global-
scanning mode, so that the program found the docking sites without
intervention of the operator. The setting for ‘‘densities’’ (angular steps) was
6, and for clusters of docking results we selected the 100 best. Promising
docking results were subject to a further test by solvating with a water layer
of ;7 A˚ and running MDS for 100 ps with particle-mesh Ewald for
electrostatic interactions (GROMACS force ﬁeld). Analysis of binding site
results was done with SPDBV 3.7 (Guex and Peitsch, 1997) and the tools
from GROMACS (Berendsen et al., 1995; Lindahl et al., 2001).
RESULTS
The model
As explained in Materials and Methods, Glut1 models were
obtained by homology with both the E. coli glycerol
phosphate transporter (Glut1A)and the E. coli lac permease
structure (Glut1B). Of these two, Glut1B presented sub-
stantially more gaps in the helical regions. In addition, a
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BLAST search ﬁnds no homologies for lac permease in the
protein mammalian database. In contrast, there are a few
human homologs for the bacterial glycerol phosphate
transporter, most notably the glucose-6-phosphate translo-
case. Hence, we did further analysis only with Glut1A. We
used the sequence of glucose-6-phosphate translocase as an
intermediate to correct residue assignments for Glut1 (see
Materials and Methods), and were thus able to model for all
492 residues of Glut1.
The reﬁned Glut1 model thus obtained by homology with
GlpT was subject to extensive validation analysis. Statistical
validations for bond lengths and angles and Ramachandran
analysis were obtained with PROCHECK, and are shown in
Table 1. This program, although permissive, is a ﬁrst test that
a model must deﬁnitely meet to be validated. The Glut1
model has no residues in the disallowed region, and has an
excellent score (0.3) for the overall G-factor (bond lengths
and angles). By comparison with our prior (Zuniga et al.,
2001) Glut1 model (Table 1), the current model has a larger
number of residues in the core. In addition, the prior G-factor
was deﬁcient for a reﬁned model. This trend continues with
the data of Table 2, obtained with WHATCHECK, in which
the Ramachandran plot appearance Z-score (RPA, col. 3) for
Glut1 is exceedingly good (0.8). In all likelihood, the BBC
and IOD parameters appear excessive only because the
databases are not optimized for membrane proteins. Still, the
Glut1 model scores are similar to those of the crystallo-
graphic structures. In several instances in Tables 1 and 2, the
scores for Glut1 are better than those for the crystal
structures. This is only due to the fact that the crystal
structures have not had extensive reﬁnement. Still, the scores
also mean that no shortcomings are apparent for the Glut1
structure.
Fig. 1 shows a cartoon representation of the three-
dimensional structure of the Glut1 homology model. The
helical arrangement shown is the same as what is emerging
as a characteristic of the MFS fold, namely, helices 1, 2, 4, 5,
7, 8, 10, and 11 immersed in a box formed by helices 3, 6, 9,
and 12. In the view from the top (Fig. 1 b), Glut1 dimensions
are ;36 3 26 A˚, and from the bottom (Fig. 1 c), ;46 by 27
A˚. Its height is ;61 A˚ and its shape is trapezoidal (Fig. 1 a).
The tilts for the different helices vary, as shown in Fig. 1,
b and c. Helix 10 has a small loop in the middle that
presumably adds ﬂexibility. The topology is consistent with
the experimental constraints from the literature, described in
the Introduction. As shown in Fig. 1 a, on the extracellular
side, the glycosylation site N45 is in loop 1–2, the K300 site
corresponds to loop 7–8, and the residue C429 is included
in loop 11–12. Intracellularly, loops 2–3 and 7–8 are
characterized by the common motif RXGRR. As in its GlpT
template, the long loop 6–7 (residues 208–263) presents
a short helix between residues R253 and E261.
Channel and crucial residues
The Glut1 structure is characterized by a channel across the
protein that communicates the extracellular and intracellular
TABLE 1 Ramachandran plot results and PROCHECK
summary
Ramachandran plot (%)
Structure Core Allowed Generous Disallowed Overall G-factor
Glut1* 86.7 12.4 1.0 0 0.3
GlpTy 85.4 13.5 1.1 0 3.0
LacYz 79.5 18.6 1.4 0.5 3.4
Glut1§
(old)
81.5 16.9 1.7 0 3.7
*PDB No. 1SUK.
yPDB No. 1PW4.
zPDB No. 1PV6.
§PDB No. 1JA5.
TABLE 2 WHATCHECK Z-scores for quality assessment and
statistical analysis of Glut1, GlpT, and LacY
Structure Z-score RMS Z-scores
Structure PQ RPA xNR BBC BL BA VR SCP IDD IOD
Glut1* 2.0 0.8 2.7 9.5 1.0 1.4 0.9 1.5 1.4 1.3
GlpTy 2.3 5.0 2.2 8.8 0.7 1.0 0.5 1.1 1.0 1.2
LacYz 2.4 7.9 4.7 7.8 0.6 0.8 0.2 0.3 0.6 1.2
PQ, second-generation packing quality; RPA, Ramachandran plot appear-
ance; xNR, x1/x2 rotamer normality; BBC, backbone conformation; BL,
bond lengths; BA, bond angles; V, omega angle restraints; SCP, side-chain
planarity; IDD, improper dihedral distribution; and IOD, inside/outside
distribution.
*PDB No. 1SUK.
yPDB No. 1PW4.
zPDB No. 1PV6.
FIGURE 1 Representations of Glut1. (a) Side view showing relative
positions of the helices. Residues in red represent topology constraints
derived from experimental results (explained in the text) involving N45,
K300, and C429 for the extracellular side, and motifs 89RFGRR93 and
330RAGRR for the cytoplasmic side. Glut1 measures ;35.6 3 26.3 A˚
viewed from the top, and 46.2 A˚ 3 27.2 A˚ from the bottom. Its height is
;61 A˚. (b) View from the extracellular side showing the tilt of the 12
transmembrane helices. X marks loops entering, whereas dots mark loops
exiting. (c) Cytoplasmic view; marks as above. The helix colors are in
concordance with the symmetry template found by Hirai et al. (2002). Figure
drawn using PYMOL (http://pymol.sourceforge.net/).
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environments. Only one opening is apparent at each one of
its ends. The cavities forming the channel and close to it were
determined by software (compare to Materials and Meth-
ods); Fig. 2 shows views of this channel, as well as residues
on it that are crucial for transport function and pathogenicity.
Some residues crucial for pathogenicity (Table 3) are found
in helices 2 and 4; as can be seen in Fig. 1, these structures
limit the transport channel. Other residues crucial for
pathogenicity are in the long intracellular loop 6–7, as
E247 and K256. Several residues crucial for transport of
b-D-glucose bound the channel, most of them located in
a channel segment between T310 and the Q161. This
segment is ;15 A˚ long and 7 A˚ wide. As Fig. 2 shows,
another cluster of residues crucial for pathogenicity (G91,
E146, E247, K256, and R333) appears bordering the
cytoplasmic end segment of the channel. Fig. 3 displays
a close-up view of the central segment of the channel,
highlighting residues crucial for transport and selectivity.
In addition, we explored interactions between pairs of
residues at places where the structure places two helices in
close vicinity (3–5 A˚). Table 4 lists these pairs. Interactions
with helices 3, 6, 9, and 12 were omitted for brevity, as no
pathogenic or crucial residues have been located to them yet.
Cavities
Fig. 4 a shows ‘‘cavities’’ inside the protein, including the
channel, as calculated with CASTP. The external cavity
appears to be the continuation of the channel, except for
a constriction that separates the two (extracellular end of the
channel). The two charged cavities are lined with positively
charged residues, and correspond to the Walker ATP binding
motifs A and B described and analyzed by Liu et al. (2001).
After a short (400 ps) molecular dynamics simulation, as
shown in Fig. 4 b, the extracellular end of the channel widens
and a communication opens with the external cavity. At the
same time, the intracellular end narrows and a new cavity
around the Q161 is segregated from it, the internal cavity;
this results in a constriction at that point closing the
intracellular end of the channel. Lastly, the intracellular-
charged cavity (Walker B ATP binding motif) disappears, as
an opening in its place now connects with the main channel.
Overall, during the simulation interval the channel increases
its volume by the joining of the other cavities to it, but the
internal segment of the channel (between the two observed
constrictions) is conserved. Areas and volumes of the
cavities and the changes that occur after the simulation are
shown in Table 5.
FIGURE 2 Locations of pathologic mutants, residues crucial for activity,
and surface calculated for the Glut1 transport pathway. (a) The backbone is
represented in ribbons and colored as in Fig. 1. Residues are in space-ﬁlling
mode and labeled; residues crucial for pathogenicity are in red, and those
crucial for transport in blue. Cyan denotes a motif of two consecutive
residues crucial for transport, and green denotes the Gln residues presumed
involved in selectivity. The transport pathway is denoted by a surface
representation in gray; it was calculated with the USF programs (http://
alpha2.bmc.uu.se/gerard/manuals/welcome2usf.html; Kleywegt and Jones,
1994, 1996, 1999) and read in ccp4 format into the program used for this
ﬁgure, VMD (http://www.ks.uiuc.edu/Research/vmd/; Humphrey et al.,
1996). (b) Back view, using the same colors and representations.
TABLE 3 Glut1 pathogenic mutants, resulting in DS-GLUT1
phenotype in humans
Mutation Nucleotides Location Reference
S66F TCC/TTC Helix 2 Klepper et al. (1999)
G91D GGC/GAC Loop 2–3 Klepper et al. (2001)
R126H CGC/CAC Helix 4 Brockmann et al. (2001)
R126L CGC/CTC Helix 4 Wang et al. (2000)
R126C CGC/CGT Helix 4 Pascual et al. (2002)
E146K GAA/AAA Helix 4 Wang et al. (2000)
E247D GAA/CAA Loop 6–7 Pascual et al. (2002)
K256V AAG/GTG Loop 6–7 Pascual et al. (2002)
T310I ACC/ATC Helix 8 Klepper et al. (1999)
R333W CGG/TGG Loop 8–9 Wang et al. (2000)
FIGURE 3 Side view to detail the helical ribbons surrounding the putative
channel. Helix 1 not shown for clarity. Residues that affect Glut1 function
upon mutation are highlighted (side chains shown as sticks). Residue
coding: blue, crucial for transport; orange, tryptophans lining the channel
(W388 and W412 are crucial for transport); and green, QLS and QLG
motifs.
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Docking
Fig. 5 shows space-ﬁlling displays of putative docking sites
for the substrate b-D-glucose (red) and several well-known
inhibitors of Glut1, forskolin (green), phloretin (magenta),
and CytB (blue). Glucose, forskolin, and phloretin dock to
what appears to be a common extracellular binding site near
the extracellular opening of the transport channel. In-
terestingly, forskolin and phloretin also dock to an in-
tracellular site near the intracellular opening of the transport
channel; this site coincides with the internal cavity that forms
after the simulation (Fig. 4 b). CytB docks to another site that
is located further intracellularly but also along the transport
channel described in Fig. 2 a. Details of the dockings are
given in the sticks representations of Fig. 5, b–g. Glucose
(Fig. 5 b) forms two H-bonds and its C6 interacts with
Tryptophan 65. At the extracellular site, forskolin (Fig. 5 c)
forms three H-bonds and again interacts with Trp65, and
phloretin (Fig. 5 d) also forms three H-bonds, one of them
with the aromatic N of Trp65. At its intracellular site,
forskolin (Fig. 5 e) forms ﬁve H-bonds and may interact with
Phe81, and phloretin (Fig. 5 f ) forms six H-bonds, and may
interact with Phe81. Lastly, CytB (Fig. 5 g) forms only one
H-bond, indicating docking by steric hydrophobic interac-
tions. Aside from the sites shown, all ligands except for CytB
formed other clusters of interactions with lesser scores,
which are not shown. CytB docked at only one site.
DISCUSSION
The results obtained with PROCHECK and WHATCHECK
(Tables 1 and 2) provide excellent validation for the Glut1
coordinates given here. The scores for Glut1 are as good as
TABLE 4 Helix-helix interactions; pairs of residues separated
by 3–5 A˚
Helix
intersection Residue pairs
H2–3 87–95
H2–4 122–68, 123–68, 123–71, 123–64, 123–67, 126–68,
126–69, 126–72, 127–71, 127–75, 129–72,
130–72, 130–76, 131–75, 133–72, 134–83,
135–83, 135–87, 139–87, 142–87, 142–88
H2–7 290–65
H2–11 405–77, 409–77, 409–74, 412–70, 412–72,
412–73, 412–69, 416–66, 416–67, 416–70,
420–63, 420–66
H4–5 148–151, 152–144, 152–141, 152–145, 155–144,
156–141, 156–144, 159–140, 159–144,
H5–7 289–172
H5–8 306–172, 307–173, 307–176, 310–169, 310–173,
310–172, 311–169, 311–173, 313–169, 314–165,
314–169, 317–165, 318–165, 318–166, 322–162
H7–8 306–289, 309–288
H7–10 369–284, 369–288, 372–284, 373–284, 373–285,
376–277, 376–280, 377–281, 380–277,
381–278, 384–270, 384–274, 387–270, 388–270,
388–267, 388–271
H7–11 403–271, 403–274, 406–271, 407–274, 407–275,
407–278, 408–278, 410–275, 411–275,
411–278, 411–279, 412–282, 414–279, 415–283,
415–279, 420–287, 279–411HB
H8–10 366–308, 366–309, 366–312, 369–309, 369–313,
370–316, 373–317, 373–313, 374–320,
375–320, 379–320, 379–324, 365–305HB
H10–11 399–388, 400–385, 400–388, 400–389, 400–386,
402–388, 403–385, 403–388, 404–385
Bold, pathogenic residues; italicized, residues crucial for transport. All
interactions are hydrophobic except those labeled HB (hydrogen bond).
Interactions involving helices 1, 3, 6, and 9 omitted (data available upon
request).
FIGURE 4 Glut1 cavities before and after a 400-ps molecular dynamics
simulation. (a) Starting conformation. Residues lining the transport pathway
are colored in cyan. There are in addition several cavities facing the outside
of the protein. The external cavity (magenta) is a continuation of the
channel, separated from it by an obstruction or neck. There are other cavities,
namely, a side cavity (red), and two cavities bound by charged residues
including ATP binding motifs (Walker A, orange; Walker B, violet). (b)
Conformation after 400 ps. The pathway has expanded as the Walker B
cavity has fused with it, but an internal cavity (magenta) has now appeared at
the intracellular end of the channel, separated from it by a neck. The side
cavity has divided into two: side cavity 1 (light red) and side cavity 2 (dark
red). Figure drawn using KING (http://kinemage.biochem.duke.edu/soft-
ware/king.php).
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those for the comparison crystallographic structures. The few
scores in Table 2 that exceed the accepted norm are due to
insufﬁcient inclusion of transmembrane proteins to arrive at
database parameters. A prior Glut1 model of ours, 1JA5
(Zuniga et al., 2001), was based on a helical packing scheme
for lac permease that was found inexact when that protein
was solved by crystallography (Abramson et al., 2003). We
term our prior model obsolete, and instead recommend the
use of the current one (1SUK), based on homology with
a crystallographic structure. The only qualiﬁcation is that, as
in the GlpT template, 1SUK has a very long helix 12, a result
of the mutational engineering done to stabilize the crystals of
GlpT. After even a short equilibration (200 ps), helix 12 in
1SUK breaks after Lys451, becoming a C-terminal loop
(except for a short local helix).
The structure obtained by homology analysis (and
communicated, Salas-Burgos et al., 2004, to the protein
database) is the one represented in Figs. 1, 2, and 4 a. To
examine functional aspects of the transporter, we deemed
advisable to remove from the homology structure possible
effects of the immobilization required for the crystallo-
graphic template, which is why the structure was subject to
the short 400-ps simulation described resulting in a ‘‘re-
laxed’’ structure (Fig. 4 b). It is well accepted (Carruthers,
1990) that Glut1 has two conformations for glucose binding,
one intracellular and other extracellular. From Glut1
turnover rates (120–450/s,Walmsley et al., 1998) a minimum
estimate for the time interval required for a conformational
change is ;1 ms. Obviously only a small fraction of the
entire relevant conformational space can be sampled in 400
ps. Still, the short simulation may yield partial glimpses of
the overall conformational change: an internal binding site is
formed, and the Walker B motif fuses with the channel. Both
Walker motifs have been reported to exert inﬂuence on
transport through Glut1 (Liu et al., 2001). The presence of
TABLE 5 Cavity analysis using CASTP
Time Cavity Area (nm2) Vol (nm3) N openings
0 Channel 2785.152 2438.7 3
0 External 190.409 69.3 2
0 Side 169.298 84.7 1
0 Charged ext. (Walker A) 131.336 45.1 2
0 Charged int. (Walker B) 71.386 26.3 0
100 Channel 5372.912 6027.3 15
100 Internal 93.605 58.0 2
100 Charged 164.204 50.2 2
100 Side 1 78.299 22.0 2
100 Side 2 40.645 5.1 0
FIGURE 5 Docking sites for substrates and
characteristic inhibitors of Glut1. (a) Substrates
and inhibitors at their docking sites. Slab view
showing the cavities and transport pathway of
Glut1. b-D-glucose (red ) binds extracellularly,
whereas both forskolin (green), and phloretin
(magenta) bind at extracellular and intracellular
sites. Cytochalasin B (blue) binds intracellularly.
Figure drawn using SPDBV (http://us.expasy.org/
spdbv/; Guex and Peitsch, 1997). Docking sites for
(b), glucose; (c) forskolin (extracellular); (d )
phloretin (extracellular); (e) forskolin (intracellu-
lar); ( f ) phloretin (intracellular); and (g), cytocha-
lasin B. White labels, residues; yellow sticks,
hydrogen bonds. Numbers indicate A˚ distances.
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charged cavities in our model therefore provides a possible
framework for observed modulation of transport by ATP
(Carruthers and Helgerson, 1989; Liu et al., 2001; Cloherty
et al., 2001).
The central channel is essentially formed by helices 2, 4,
5, 7, 8, and 10. The residues crucial for transport and
pathogenicity (Fig. 2) are nucleated in two groups: one
around the central channel, and the other on the long
intracellular loop. The functional consequences observed are
quite consistent with the model. The presence of solvent-
accessible residues along the transport channel (Fig. 2) is
logical in this context. In addition, a line of residues crucial
for pathogenicity (E247, K256, R333) or transport (P387,
W388) is located (Fig. 2) on or near the segment of the long
intracellular loop that delimits the transport pathway, which
again lends credence to the model.
We also explored the hydrophobic interactions between
pairs of residues at points where helices cross each other. We
hypothesized that mutations at those residues could affect
packing or stability, with consequent effects on function.
Table 4 shows these residues; as can be seen, mutations of
some of them have been already determined to result in
pathogenicity or to affect transport. It may be useful to study
what effects could result from mutations at the other sites
identiﬁed here, hitherto unexplored.
The shape of the transport pathway is noteworthy. The
entrance at the extracellular end is funnel-like (infundibulum,
Fig. 4 a), and at its bottom we ﬁnd the docking sites
described below. As for the intracellular end, interestingly,
the horn-shaped pathway incurvates so that its exit is located
almost to the side of the protein. It also expands into
a cylindrical cavity ;12 A˚ in diameter. Fittingly, prior
observations from Carruthers’ laboratory (Heard et al., 2000;
Cloherty et al., 2002) of a delay in the substrate exiting the
protein during inﬂux had been already interpreted in terms of
a cytoplasmic cavity in Glut1 (Heard et al., 2000; Cloherty
et al., 2002). In addition, the position of the cytoplasmic
oriﬁce near the side of the protein would allow both
monomer cytoplasmic cavities to join into a larger one for a
dimer, as also predicted by Carruthers and co-workers (Heard
et al., 2000; Cloherty et al., 2002).
Glucose (b-D-glucopyranose) is at the same time
hydrophilic due to its OH groups, and hydrophobic due to
the pyranose ring. In E. coli maltoporin, a ‘‘greasy slide’’
made of aromatic residues has been linked to sugar transport
(Van Gelder et al., 2002). Interestingly, in our model the
internal segment of the transport pathway (the channel) is
lined by both hydrophilic and hydrophobic residues. Among
them, many have been mutated and shown to be crucial for
transport activity—Q161, R126, Q279, Q282, N317, T321,
W65, W388, W412, and V165 (all cited above). These
characteristics are shown in detail in Fig. 3.
The conserved QLS motif starting at Q279 has been
recognized as crucial for the selectivity of Gluts for the
transported sugars (Seatter et al., 1998; Olsowski et al.,
2000). Fittingly, it is near the extracellular entrance of the
channel (Fig. 3), possibly positioned to discriminate against
nonsubstrates attempting to enter the cell. Moreover, the
sequence at that point is (279)QLSQQLS. As pointed out
recently (Li et al., 2004), at the second QLS site (one helix
turn up from the ﬁrst, at Q283), except for Glut11, the QQLS
motif is very well conserved in all Gluts (1–14). This site is at
the very extracellular end of the channel (Fig. 3), which forms
a bottleneck there (Fig. 4 b). It is easy to speculate that this
site may be also involved in selectivity, perhaps somehow
interacting with the QLS site down the helix. Lastly, there is
a QLG motif starting at position 161 (Fig. 3). Mueckler et al.
(1994) established that mutations of the well-conserved
Q161 residue decreased transport 10–50-fold. In our model,
this QLG motif is at the intracellular end of the channel; if by
analogy with the QLS this motif can also select substrates, it
would be positioned to select molecules exiting the cell.
Even if speculative, there is a mechanism for substrate
migration consistent with the model. It seems unlikely that
glucose would form more than one or temporarily two
H-bonds at any time. Formation of more H-bonds would
stabilize the substrate in position, keeping it in place rather
than facilitating migration. However, if glucose forms
approximately one H-bond at a time, it could migrate along
the channel by rolling along the wall, forming a new H-bond
forward as the one in the back is being broken. Such rolling
and sequential H-bonding has been seen by us in molecular
dynamics simulations (unpublished data); H-bonding of the
glucose substrate with crucial residues was seen in
a molecular dynamics simulation done with a Glut3 model
(Dwyer, 2001). Moreover, the role of the hydrophobic
residues would be to develop a stabilizing interaction with
the hydrophobic C6 region of the substrate as it passes by.
Such an interaction is seen in the glucose docking site shown
in Fig. 5, a and b.
Docking sites
As can be seen in Fig. 5, glucose, forskolin, and phloretin
dock at sites in very close mutual proximity on the exofacial
vestibule of the Glut1 model; the model is consistent with
great steric interference by the inhibitors with the exofacial
glucose docking site. Regarding forskolin and glucose, in an
analysis of interactions of both with Glut1 it was concluded
that a carbohydrate was recognized within the forskolin
functionalities (Joost et al., 1988). As for phloretin, its
phenol ring appears to sit in the same pocket as glucose, and
is stabilized in place by three H-bonds to its benzene-1,3,5-
triol ring. As one would expect, the inhibitors develop more
interactions than glucose with the protein (Fig. 5), which
would of course stabilize them in place so as to obstruct
glucose docking.
The interactions of forskolin with its exofacial site
resemble those of glucose (compare to K38, W65, Fig. 5,
b and c). We speculate therefore that there may be a potential
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docking site for glucose at or near the forskolin endofacial
site, but it is not made evident in the particular conformation
sampled by the simulation. If that would be the case, one
would predict competitive inhibition of glucose transport by
both forskolin and phloretin at both exofacial and endofacial
sites. There are ﬁndings in the kinetic literature that are
consistent with two binding sites (Helgerson and Carruthers,
1987) and the inherent complex behavior (Carruthers, 1990).
Interestingly, anomalous kinetics in Glut1 have also been
accounted for in a kinetic scheme (Hernandez et al., 1996)
with two sites and two conformational states.
As mentioned above, the putative recognition site for
sugars, the QLS motif, is at the extracellular end of the
channel, and there is a QLG site at the intracellular end of the
channel. The docking algorithm does not ﬁnd glucose at those
sites. It is conceivable that this may be due to the particular
channel conformation sampled in the simulation. However,
gossypol, which has been linked to inhibition of glucose
transport (Christensen et al., 1987), is found at sites inside the
channel by the docking algorithm (data not shown). From this
we presume that if glucose would bind strongly inside the
channel, the docking algorithm would ﬁnd it there; it does
not. This seems logical; as the substrate enters the channel, it
would be most efﬁcient if it would traverse it quickly. In this
context, selectivity sites inside the channel would allow
passage or not, but would not bind substrate tightly.
Concerning another well-known Glut1 inhibitor, CytB,
the docking algorithm found for it only one cluster with very
high score, and no other clusters at all. It was on the
intracellular side, as experiments had shown (Helgerson and
Carruthers, 1987; Carruthers, 1990). However, the site (Fig.
5 g) is different than that predicted by several other studies
(with interactions with helices 10 and 11; Baldwin, 1993)
near W388 (Garcia et al., 1992; Kasahara and Kasahara,
1998). Still, the present ﬁndings are internally consistent in
that the CytB site is close (3 A˚) to the endofacial site for
forskolin and phloretin (Fig. 5, a and e–f), and close enough
to the endofacial channel opening to interfere with glucose
passage. It seems noteworthy that the present CytB site
appears to be a pocket lined with several positively charged
and polar residues (Fig. 5 g), which might attract a molecule
with moderate dipole moment such as CytB.
The role of the cavities described here is unclear. On the
other hand, there is a body of literature on compounds that
interact with Glut1 and may exert regulatory inﬂuence on it,
namely nucleotides and analogs, ﬂavonoids, antiestrogens,
androgens, antiandrogens, barbiturates, and catechins (Hon-
kanen et al., 1995; Afzal et al., 2002; Martin et al., 2003;
Naftalin et al., 2003). Perhaps the cavities may act as binding
sites for such modulators.
In summary, there is ample evidence to validate the
present model of Glut1. It arises from a crystallographic
structure template, it stands optimally in terms of statistics
and energetics, and accounts for practically all published
biochemical, physiological, and mutagenesis evidence.
Some aspects that remain to be elucidated include the
binding site for CyB and the existence and location of an
endofacial binding site(s) for glucose. Still, the present
model may be useful in elucidating the connection between
the structure and the function of Glut1 and related molecules.
The present Glut1 coordinates have been communicated
to the RCSB Protein Data Bank (entry No. 1SUK).
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